English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Decreased expression of peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) is implicated in the pathophysiology of Parkinson’s disease (PD). However, our understanding of the mechanism regulating the PGC-1α expression is still limited. We sought to determine whether the epigenetic modification of  PPARGC1A  (the gene encoding PGC-1α) could account for its diminished expression. We performed a study of  PPARGC1A  risk-SNP genotypes, methylation level, and the expression in blood from 171 subjects. The mean DNA methylation level of  PPARGC1A  intron 1 in patients with PD was higher than that in the controls (7.18 ± 1.74 vs. 6.36 ± 1.28,  P  = 0.007). A detailed comparison of the DNA methylation level at each CpG site showed that CpG_1, CpG_13.14, CpG_17.18, and CpG_20 were significantly hypermethylated in patients with PD. There was a significant negative correlation between  PPARGC1A  methylation and expression level ( R  = −0.404,  P  < 0.001). We found no correlations between the  PPARGC1A  methylation level and the clinical features, while the CpG_13.14 site methylation level was positively correlated with H&Y stage ( R  = 0.246,  P  = 0.020) and was increased in people carrying the rs2970848 AA genotype compared with that in carriers of the AG/GG genotype (7.27 ± 1.86 vs. 6.65 ± 1.92,  P  = 0.032). Our results support a link between  PPARGC1A  methylation, gene expression, and variability, which indicated that a novel epigenetic regulatory mechanism controlling  PPARGC1A  expression influences PD pathogenesis.

Hypermethylation of the Gene Coding for PGC-1α in Peripheral Blood Leukocytes of Patients With Parkinson’s Disease